Cargando…
Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial
IMPORTANCE: The global prevalence of myopia is predicted to approach 50% by 2050, increasing the risk of visual impairment later in life. No pharmacologic therapy is approved for treating childhood myopia progression. OBJECTIVE: To assess the safety and efficacy of NVK002 (Vyluma), a novel, preserva...
Autores principales: | Zadnik, Karla, Schulman, Erica, Flitcroft, Ian, Fogt, Jennifer S., Blumenfeld, Louis C., Fong, Tung M., Lang, Eric, Hemmati, Houman D., Chandler, Simon P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236322/ https://www.ncbi.nlm.nih.gov/pubmed/37261839 http://dx.doi.org/10.1001/jamaophthalmol.2023.2097 |
Ejemplares similares
-
Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
por: Cui, Can, et al.
Publicado: (2021) -
Effect of 0.02% and 0.01% atropine on astigmatism: a two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2022) -
Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial
por: Wang, Ming, et al.
Publicado: (2023) -
Effect of atropine 0.01% on progression of myopia
por: Sen, Snigdha, et al.
Publicado: (2022) -
Effects of atropine 0.01% on refractive errors in children with myopia
por: Zhu, Xingxue, et al.
Publicado: (2023)